Life sciences briefing: Wednesday, Dec. 12, 2007
TODAY’S HEADLINES:
Topical Botox maker Revance gets $43M, option to be acquired by Medicis (release)
Reva Medical draws $42M for resorbable stents (release)
AccentCare raises $8M for senior home-care services (VentureWire, sub req’d)
Light Dimensions aims for $6M for light-based skin treatment (VW)
Carigent pulls in $2M for nanoparticle drugs (release)
Celtic Pharma shoots for $1.5B in two drug-investment funds (VW)
Topical Botox developer Revance gets $43M, option to be acquired by Medicis — Mountain View, Calif.-based Revance Therapeutics, a developer of… Continue Reading
Talecris, a ludicrously large IPO, and the beginning of the end for private equity?
(UPDATED: See below.) Is the air starting to hiss out of the private-equity bubbble? Looking at Talecris Biotherapeutics, a stodgy biotech controlled by private-equity firms Cerberus Capital Management and Ampersand Ventures that filed to raise as much as $1 billion in an initial offering last Friday, you’d be perfectly justified in thinking so.
For starters, the IPO is just ridiculously huge. Biotech offerings that raise more than $100 million are fairly rare; this year, for instance, only three… Continue Reading